Trevena Inc (TRVN) Expected to Post Earnings of -$0.26 Per Share

Equities research analysts expect Trevena Inc (NASDAQ:TRVN) to post earnings of ($0.26) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Trevena’s earnings, with the highest EPS estimate coming in at ($0.24) and the lowest estimate coming in at ($0.27). Trevena reported earnings of ($0.67) per share in the same quarter last year, which indicates a positive year over year growth rate of 61.2%. The firm is expected to announce its next earnings report on Wednesday, March 14th.

On average, analysts expect that Trevena will report full-year earnings of ($1.23) per share for the current fiscal year, with EPS estimates ranging from ($1.25) to ($1.21). For the next year, analysts forecast that the business will post earnings of ($0.97) per share, with EPS estimates ranging from ($1.17) to ($0.82). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Trevena.

A number of equities analysts have commented on TRVN shares. Oppenheimer restated a “buy” rating and issued a $5.00 price target on shares of Trevena in a research report on Monday, November 13th. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Trevena in a research report on Wednesday, November 8th. Needham & Company LLC reduced their price target on shares of Trevena from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, November 8th. Zacks Investment Research upgraded shares of Trevena from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research report on Wednesday, October 18th. Finally, Barclays lowered shares of Trevena from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $15.00 to $2.50 in a research report on Monday, October 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $7.35.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System raised its stake in shares of Trevena by 0.5% in the second quarter. California State Teachers Retirement System now owns 97,107 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 500 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Trevena by 30.1% in the second quarter. Rhumbline Advisers now owns 64,251 shares of the biopharmaceutical company’s stock worth $148,000 after acquiring an additional 14,880 shares during the last quarter. TIAA CREF Investment Management LLC raised its stake in shares of Trevena by 8.3% in the second quarter. TIAA CREF Investment Management LLC now owns 237,045 shares of the biopharmaceutical company’s stock worth $545,000 after acquiring an additional 18,190 shares during the last quarter. Alliancebernstein L.P. raised its stake in shares of Trevena by 51.9% in the second quarter. Alliancebernstein L.P. now owns 55,300 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 18,900 shares during the last quarter. Finally, Teachers Advisors LLC raised its stake in shares of Trevena by 26.4% in the second quarter. Teachers Advisors LLC now owns 98,153 shares of the biopharmaceutical company’s stock worth $226,000 after acquiring an additional 20,482 shares during the last quarter. 56.74% of the stock is owned by institutional investors.

Trevena (TRVN) traded up $0.12 during trading hours on Wednesday, reaching $1.63. 1,797,798 shares of the company’s stock were exchanged, compared to its average volume of 455,047. The firm has a market capitalization of $94.07, a price-to-earnings ratio of -0.99 and a beta of -0.51. Trevena has a 52-week low of $1.34 and a 52-week high of $8.00. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.92 and a current ratio of 4.92.

WARNING: This news story was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.com-unik.info/2018/02/10/trevena-inc-trvn-expected-to-post-earnings-of-0-26-per-share.html.

About Trevena

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Get a free copy of the Zacks research report on Trevena (TRVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit